GR1009922B - Capsules against cholesterol - Google Patents
Capsules against cholesterol Download PDFInfo
- Publication number
- GR1009922B GR1009922B GR20190100256A GR20190100256A GR1009922B GR 1009922 B GR1009922 B GR 1009922B GR 20190100256 A GR20190100256 A GR 20190100256A GR 20190100256 A GR20190100256 A GR 20190100256A GR 1009922 B GR1009922 B GR 1009922B
- Authority
- GR
- Greece
- Prior art keywords
- vitamin
- cholesterol
- preparation
- formulation
- lipox
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 32
- 239000002775 capsule Substances 0.000 title claims abstract description 6
- 235000012000 cholesterol Nutrition 0.000 title claims description 12
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000012141 concentrate Substances 0.000 claims abstract description 5
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims abstract description 3
- 240000002234 Allium sativum Species 0.000 claims abstract description 3
- 244000075850 Avena orientalis Species 0.000 claims abstract description 3
- 235000007319 Avena orientalis Nutrition 0.000 claims abstract description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 3
- 241001312519 Trigonella Species 0.000 claims abstract description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 3
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960001231 choline Drugs 0.000 claims abstract description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 3
- 229910052802 copper Inorganic materials 0.000 claims abstract description 3
- 239000010949 copper Substances 0.000 claims abstract description 3
- 229960000304 folic acid Drugs 0.000 claims abstract description 3
- 235000019152 folic acid Nutrition 0.000 claims abstract description 3
- 239000011724 folic acid Substances 0.000 claims abstract description 3
- 235000004611 garlic Nutrition 0.000 claims abstract description 3
- 229960000367 inositol Drugs 0.000 claims abstract description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 3
- 229910052742 iron Inorganic materials 0.000 claims abstract description 3
- 239000011777 magnesium Substances 0.000 claims abstract description 3
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 3
- 229930182817 methionine Natural products 0.000 claims abstract description 3
- 229940057059 monascus purpureus Drugs 0.000 claims abstract description 3
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 3
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 3
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 3
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960002477 riboflavin Drugs 0.000 claims abstract description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000011669 selenium Substances 0.000 claims abstract description 3
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 3
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 3
- 229960003495 thiamine Drugs 0.000 claims abstract description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 3
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 3
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 3
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 3
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 3
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 3
- 239000011718 vitamin C Substances 0.000 claims abstract description 3
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 3
- 239000011701 zinc Substances 0.000 claims abstract description 3
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 abstract description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
ΠΕΡΙΓΡΑΦΗ DESCRIPTION
ΚΑΨΟΥΛΕΣ ΓΙΑ ΑΝΤΙΜΕΤΩΠΙΣΗ ΧΟΛΗΣΤΕΡΙΝΗΣ CAPSULES TO ADDRESS CHOLESTEROL
Η εφεύρεση αναφέρεται στην δημιουργία σκευάσματος (Lipox) το οποίο επαναφέρει τις τιμές της χοληστερόλης στο αίμα στα φυσιολογικά όρια μια και η υπερβολική χοληστερόλη στο αίμα, ως γνωστόν αυξάνει τον κίνδυνο καρδιακών προσβολών και εγκεφαλικών επεισοδίων και είναι ένας συνδυασμός φυτικών πρώτων υλών. The invention refers to the creation of a preparation (Lipox) which restores blood cholesterol values to normal limits since excessive blood cholesterol is known to increase the risk of heart attacks and strokes and is a combination of plant raw materials.
Η μοναδικότητα του σκευάσματος οφείλεται στον γεγονός ότι δεν περιέχει στατινες. Οι στατινες, σε όλα τα φαρμακευτικά σκευάσματα, εμποδίζουν μια ουσία που το ήπαρ χρειάζεται για να συνθέσει τη χοληστερόλη, κάνοντας το ήπαρ να απομακρύνει τη χοληστερόλη από το αίμα, που όμως έχει αποδεχτεί ότι έχουν σοβαρές παρενέργειες. The uniqueness of the preparation is due to the fact that it does not contain statins. Statins, in all pharmaceutical formulations, block a substance that the liver needs to synthesize cholesterol, causing the liver to remove cholesterol from the blood, but it has been accepted that they have serious side effects.
Aυτές οι παρενέργειες δεν έχουν καμία σχέση με το σκεύασμα ( Lipox). Πρόκειται για απολύτως φυσικό σκεύασμα (το οποίο δεν έχει απολύτως καμία σχέση με τις στατινες και) στο οποίο ΔΕΝ υπάρχουν χημικώς παρασκευαζόμενες ουσίες. These side effects have nothing to do with the preparation (Lipox). It is a completely natural preparation (which has absolutely nothing to do with statins) in which there are NO chemically prepared substances.
Η πρωτοποριακή σύνθεση του σκευάσματος ( Lipox) το καθιστούν ισχυρότερο προϊόν για την αντιμετώπιση της χοληστερίνης. The innovative composition of the formulation (Lipox) make it a stronger product for dealing with cholesterol.
Περιέχει συμπυκνώματα βοτάνων, βιταμίνες, μέταλλα και αμινοξέα, τα οποία δρουν και καθορίζουν σε μεγάλο βαθμό τα επίπεδα της χοληστερίνης. It contains herbal concentrates, vitamins, minerals and amino acids, which act and largely determine cholesterol levels.
Το σκεύασμα ( Lipox) με τα βασικά συστατικά του μειώνει το επίπεδο των τριγλυκεριδίων και της επιβλαβούς χοληστερίνης (LDL και VLDL) στο αίμα, ενώ αντίθετα αυξάνει το επίπεδο της επωφελούς χοληστερίνης (HDL), ενώ συμπληρώνεται από δομικά στοιχειά τα όποια βοηθούν στη ρύθμιση της ενδογενούς και της διατροφικής χοληστερόλης. Με αποτελεσματικό τρόπο εμποδίζει την υπερβολική συσσώρευση των αιμοπεταλίων και δρα προστατευτικά κατά της αρτηριοσκλήρυνσης. The preparation (Lipox) with its main ingredients reduces the level of triglycerides and harmful cholesterol (LDL and VLDL) in the blood, while on the contrary it increases the level of beneficial cholesterol (HDL), while it is supplemented by structural elements that help to regulate endogenous and dietary cholesterol. It effectively prevents the excessive accumulation of blood platelets and acts protectively against arteriosclerosis.
Με τη ρυθμιστική του δράση στους β' υποδοχείς προστατεύει από κάθε υπερτασική & βρογχοσπασμική κρίση. With its regulatory action on b receptors it protects against every hypertensive & bronchospasm crisis.
Ταυτόχρονα υποστηρίζει τον φυσικό, αυτορρυθμιζόμενο, προστατευτικό μηχανισμό του σώματος και αποκαθιστά τις φυσικές ισορροπίες του οργανισμού. Υποβοηθά τις κύριες καρδιακές λειτουργίες - ελέγχει τη δράση του συμπαθητικού συστήματος, αποτρέποντας τους κινδύνους δυσλειτουργίας του καρδιαγγειακού συστήματος Ελέγχει την ταχυκαρδία, δεν προκαλεί βραδυκαρδία. Έχει καρδιοτονωτική δράση χωρίς δυσμενείς συνέπειες στην σεξουαλική λειτουργία, προσφέροντας ευεξία και ηρεμία. At the same time, it supports the body's natural, self-regulating, protective mechanism and restores the body's natural balance. Supports the main cardiac functions - controls the activity of the sympathetic system, preventing the risks of cardiovascular system dysfunction Controls tachycardia, does not cause bradycardia. It has a cardiotonic effect without adverse effects on sexual function, offering well-being and calmness.
Εν κατακλείδι η μοναδικότητα του σκευάσματος έγκειται στα εξής In conclusion, the uniqueness of the preparation lies in the following
Δεν περιέχει στατινες. Does not contain statins.
Δεν έχει παρενέργειες ενώ παράλληλα αντιμετωπίζει τη χοληστερίνη πολύ πιο αποτελεσματικά από τα συνταγογραφούμενα φάρμακα. It has no side effects while treating cholesterol much more effectively than prescription drugs.
Είναι το μονό σκεύασμα το οποίο δεν μειώνει μόνο την κακή χοληστερίνη, αλλά αυξάνει την καλή και ταυτόχρονα ρευστοποιεί και την αθηροματική πλάκα, γεγονός το οποίο καταδεικνύεται σαφέστατα με αιματολογικές εξετάσεις πριν και μετά την λήψη του It is the only preparation that not only reduces bad cholesterol, but also increases good cholesterol and at the same time liquefies atherosclerotic plaque, a fact that is clearly demonstrated by blood tests before and after taking it
σκευάσματος formulation
Το σκεύασμα αυτό έχει την μορφή κονεως η οποία εσωκλείεται σε κάψουλες και προκύπτει από την αναμικτική διεργασία ,για χρονικό διάστημα 10-15 λεπτών , φυτικών πρώτων υλών υπό μορφή συμπυκνωμάτων.. This preparation is in the form of a powder which is enclosed in capsules and results from the mixing process, for a period of 10-15 minutes, of plant raw materials in the form of concentrates.
Η κάθε κάψουλα ( Lipox) χαρακτηρίζεται ότι αποτελείται από Each capsule (Lipox) is characterized as consisting of
Σκόρδο Συμπύκνωμα (55 % - 75 %), Βρώμη (10 % - 15 %) , Βιταμίνη C (5 %- 10%), Κόκκινη Μαγιά (5 %- 10%),Τριγονελλα (5 %- 10%), Χολινη( 2 % - 6 %), Ινοσπολη (2 % -6 %), Μεθιονινη (2 % - 6 %), Σόγια Λεκιθίνη (2 % - 6 %), Παντοθενικο οξύ (1 %- 4 %) , Νιασινη (1 % - 2,5 %), Βιταμίνη Β6 ( 0.8 % - 2,5 %), Ψευδάργυρος (0.5 % - 2,5 %), Σίδηρος (0.5 % - 2,5 %) , Βιταμίνη Β2 ( 0,3 %- 0,7 %), Βιταμίνη Β1 (0,15 % - 0,25) , Φολικό Οξύ ( 0.09 % - 0,12), Μαγνήσιο ( 0,05 % - 0,08 %), Σελήνιο ( 0,01 %- 0,02 %), Χαλκός ( 0.009 % - 0,012), Βιταμίνη Β12 ( 0,00030 % - 0,00040 %) Garlic Concentrate (55% - 75%), Oats (10% - 15%), Vitamin C (5% - 10%), Red Yeast (5% - 10%), Trigonella (5% - 10%), Choline ( 2 % - 6 %), Inositol (2 % -6 %), Methionine (2 % - 6 %), Soy Lecithin (2 % - 6 %), Pantothenic Acid (1 % - 4 %), Niacin (1 % - 2.5 %), Vitamin B6 (0.8 % - 2.5 %), Zinc (0.5 % - 2.5 %), Iron (0.5 % - 2.5 %), Vitamin B2 ( 0.3 % - 0, 7 %), Vitamin B1 (0.15 % - 0.25), Folic Acid ( 0.09 % - 0.12), Magnesium ( 0.05 % - 0.08 %), Selenium ( 0.01 % - 0, 02 %), Copper ( 0.009 % - 0.012), Vitamin B12 ( 0.00030 % - 0.00040 %)
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20190100256A GR1009922B (en) | 2019-06-13 | 2019-06-13 | Capsules against cholesterol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20190100256A GR1009922B (en) | 2019-06-13 | 2019-06-13 | Capsules against cholesterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GR20190100256A GR20190100256A (en) | 2021-01-19 |
| GR1009922B true GR1009922B (en) | 2021-02-01 |
Family
ID=74554239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20190100256A GR1009922B (en) | 2019-06-13 | 2019-06-13 | Capsules against cholesterol |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR1009922B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017119808A1 (en) * | 2016-01-08 | 2017-07-13 | Inqpharm Group Sdn Bhd | Garlic compositions |
| GR20190200012U (en) * | 2018-08-10 | 2020-04-15 | Χρηστος Αναστασιου Γεωργιαδης | Cholesterol capsules |
-
2019
- 2019-06-13 GR GR20190100256A patent/GR1009922B/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017119808A1 (en) * | 2016-01-08 | 2017-07-13 | Inqpharm Group Sdn Bhd | Garlic compositions |
| GR20190200012U (en) * | 2018-08-10 | 2020-04-15 | Χρηστος Αναστασιου Γεωργιαδης | Cholesterol capsules |
Non-Patent Citations (1)
| Title |
|---|
| HOUSTON, M.C. ; FAZIO, S. ; CHILTON, F.H. ; WISE, D.E. ; JONES, K.B. ; BARRINGER, T.A. ; BRAMLET, D.A.: "Nonpharmacologic Treatment of Dyslipidemia", PROGRESS IN CARDIOVASCULAR DISEASES., SAUNDERS, PHILADELPHIA, PA., US, vol. 52, no. 2, 1 September 2009 (2009-09-01), US, pages 61 - 94, XP026807283, ISSN: 0033-0620 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GR20190100256A (en) | 2021-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications | |
| JP2015524477A5 (en) | ||
| WO2010065162A1 (en) | Composition for the use to treat alzheimer' s disease | |
| Chen et al. | Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy | |
| Ghaffari et al. | Effects of turmeric on homocysteine and fetuin-A in patients with nonalcoholic fatty liver disease: A randomized double-blind placebo-controlled study | |
| CA2645440A1 (en) | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition | |
| Przybyłowska et al. | Therapeutic potential of multifunctional derivatives of cholinesterase inhibitors | |
| Majeed et al. | Comparative evaluation of Nigella sativa (Kalonji) and simvastatin for the treatment of hyperlipidemia and in the induction of hepatotoxicity. | |
| GR20190200012U (en) | Cholesterol capsules | |
| JP2020533296A5 (en) | ||
| GR1009922B (en) | Capsules against cholesterol | |
| US8197871B2 (en) | Composition for headache treatment | |
| US20150157672A1 (en) | Kits and methods for sustained weight loss | |
| Bicer et al. | Effect of resveratrol administration on muscle glycogen levels in rats subjected to acute swimming exercise | |
| Siddiqui et al. | Role of herbal formulation of garlic on lipid profile in patients with type 2 diabetes related dyslipidemia | |
| Fukushima et al. | The effect of N-(α-methylbenzyl) linoleamide on experimental atherosclerosis in rabbits | |
| US20170035728A1 (en) | Compositions for Improved Body Composition | |
| Duan et al. | Effect of crude-herb moxibustion on blood lipids in rats with dyslipidemia | |
| WO2015092763A1 (en) | Nutritional composition for the prevention and treatment of copd and related symptoms | |
| CA2530660C (en) | Combinations of vasoprotective agents and formulations containing them | |
| Qudoos et al. | Single blind placebo-controlled study on comparision of effects of zingiber officinale before and after treatment in hyperlipidemia | |
| CA2687107A1 (en) | Branched-chain amino acid composition for improving skeletal muscle protein metabolism | |
| Stephens et al. | Aluminum and Alzheimer’s disease | |
| US7993685B2 (en) | Branched-chain amino acid composition for improving skeletal muscle protein metabolism | |
| Ouédraogo et al. | Spirulina and biochemical blood parameters of wistar Rats (Rattus norvegicus) in growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PG | Patent granted |
Effective date: 20210316 |